Cumberland Pharmaceuticals Stock Gross Profit
CPIX Stock | USD 1.65 0.08 5.10% |
Cumberland Pharmaceuticals fundamentals help investors to digest information that contributes to Cumberland Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cumberland Stock. The fundamental analysis module provides a way to measure Cumberland Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cumberland Pharmaceuticals stock.
Last Reported | Projected for Next Year | ||
Gross Profit | 28.5 M | 33.6 M | |
Gross Profit Margin | 0.72 | 0.94 |
Cumberland | Gross Profit |
Cumberland Pharmaceuticals Company Gross Profit Analysis
Cumberland Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Cumberland Pharmaceuticals Gross Profit | 32.89 M |
Most of Cumberland Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cumberland Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cumberland Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for Cumberland Pharmaceuticals is extremely important. It helps to project a fair market value of Cumberland Stock properly, considering its historical fundamentals such as Gross Profit. Since Cumberland Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cumberland Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cumberland Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cumberland Gross Profit Historical Pattern
Today, most investors in Cumberland Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cumberland Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's gross profit growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cumberland Pharmaceuticals gross profit as a starting point in their analysis.
Cumberland Pharmaceuticals Gross Profit |
Timeline |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition |
According to the company disclosure, Cumberland Pharmaceuticals reported 32.89 M of gross profit. This is 98.53% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The gross profit for all United States stocks is 99.88% higher than that of the company.
Cumberland Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cumberland Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cumberland Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics of similar companies.Cumberland Pharmaceuticals is currently under evaluation in gross profit category among related companies.
Cumberland Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cumberland Pharmaceuticals from analyzing Cumberland Pharmaceuticals' financial statements. These drivers represent accounts that assess Cumberland Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cumberland Pharmaceuticals' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 79.3M | 44.7M | 69.6M | 25.6M | 29.4M | 28.0M | |
Enterprise Value | 72.6M | 37.1M | 58.6M | 25.7M | 29.6M | 28.1M |
Cumberland Fundamentals
Return On Equity | -0.19 | ||||
Return On Asset | -0.0444 | ||||
Profit Margin | (0.16) % | ||||
Operating Margin | (0.30) % | ||||
Current Valuation | 21.88 M | ||||
Shares Outstanding | 14.18 M | ||||
Shares Owned By Insiders | 44.05 % | ||||
Shares Owned By Institutions | 15.56 % | ||||
Number Of Shares Shorted | 16.97 K | ||||
Price To Earning | (16.05) X | ||||
Price To Book | 0.78 X | ||||
Price To Sales | 0.58 X | ||||
Revenue | 39.55 M | ||||
Gross Profit | 32.89 M | ||||
EBITDA | (710.85 K) | ||||
Net Income | (6.28 M) | ||||
Cash And Equivalents | 18.22 M | ||||
Cash Per Share | 1.24 X | ||||
Total Debt | 18.43 M | ||||
Debt To Equity | 0.50 % | ||||
Current Ratio | 1.80 X | ||||
Book Value Per Share | 2.10 X | ||||
Cash Flow From Operations | 6.09 M | ||||
Short Ratio | 1.51 X | ||||
Earnings Per Share | (0.44) X | ||||
Target Price | 8.5 | ||||
Number Of Employees | 91 | ||||
Beta | 0.17 | ||||
Market Capitalization | 22.12 M | ||||
Total Asset | 81.78 M | ||||
Retained Earnings | (17.49 M) | ||||
Working Capital | 7.73 M | ||||
Current Asset | 66.96 M | ||||
Current Liabilities | 11.69 M | ||||
Net Asset | 81.78 M |
About Cumberland Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cumberland Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cumberland Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cumberland Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cumberland Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cumberland Stock
0.72 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.73 | ME | 23Andme Holding | PairCorr |
Moving against Cumberland Stock
0.88 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
0.74 | DSGN | Design Therapeutics Downward Rally | PairCorr |
0.72 | DOMH | Dominari Holdings | PairCorr |
0.5 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cumberland Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cumberland Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cumberland Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cumberland Pharmaceuticals to buy it.
The correlation of Cumberland Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cumberland Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cumberland Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cumberland Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cumberland Pharmaceuticals Piotroski F Score and Cumberland Pharmaceuticals Altman Z Score analysis. For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Cumberland Stock analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Cumberland Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. If investors know Cumberland will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cumberland Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 2.766 | Quarterly Revenue Growth 0.025 | Return On Assets (0.04) | Return On Equity (0.19) |
The market value of Cumberland Pharmaceuticals is measured differently than its book value, which is the value of Cumberland that is recorded on the company's balance sheet. Investors also form their own opinion of Cumberland Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cumberland Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cumberland Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cumberland Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cumberland Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cumberland Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.